NCT05552781View on ClinicalTrials.gov

H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

August 26, 2022

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

H002 capsule

Small molecule, Capsule

Trial Locations (8)

20030

RECRUITING

Shanghai Chest Hospital, Shanghai

150081

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Haerbin

310000

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

310003

RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

410000

RECRUITING

Hunan Cancer Hospital, Changsha

430022

NOT_YET_RECRUITING

Union Hospital Affiliated to Tongji Medical College Huazhong University of Science and Technology, Wuhan

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

610044

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
collaborator

R&G Pharma Studies Co.,Ltd.

INDUSTRY

lead

RedCloud Bio

INDUSTRY